Bicara Therapeutics (NASDAQ:BCAX) Earns Overweight Rating from Analysts at Morgan Stanley

Equities researchers at Morgan Stanley started coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note issued to investors on Tuesday, Briefing.com reports. The firm set an “overweight” rating and a $35.00 price target on the stock. Morgan Stanley’s target price points to a potential upside of 43.15% from the stock’s previous close.

A number of other analysts have also commented on BCAX. TD Cowen assumed coverage on Bicara Therapeutics in a research note on Tuesday. They issued a “buy” rating for the company. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a “buy” rating and a $47.00 price objective for the company.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX opened at $24.45 on Tuesday. Bicara Therapeutics has a 12 month low of $21.05 and a 12 month high of $27.94.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now directly owns 4,303,418 shares in the company, valued at $77,461,524. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, major shareholder James E. Flynn bought 70,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the purchase, the insider now owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The stock was bought at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the purchase, the director now directly owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.